{
    "id": 26560,
    "fullName": "LYPD3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "LYPD3 positive indicates the presence of the LYPD3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 27076,
        "geneSymbol": "LYPD3",
        "terms": [
            "LYPD3",
            "C4.4A"
        ]
    },
    "variant": "positive",
    "createDate": "05/09/2017",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10823,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 1129980 decreased viability of an LYPD3 (C4.4A)-expressing pancreatic adenocarcinoma cell line in culture (PMID: 28292941).",
            "molecularProfile": {
                "id": 27809,
                "profileName": "LYPD3 positive"
            },
            "therapy": {
                "id": 5651,
                "therapyName": "BAY 1129980",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8854,
                    "pubMedId": 28292941,
                    "title": "Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28292941"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10822,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 1129980 decreased viability of an LYPD3 (C4.4A)-expressing breast adenocarcinoma cell line in culture (PMID: 28292941).",
            "molecularProfile": {
                "id": 27809,
                "profileName": "LYPD3 positive"
            },
            "therapy": {
                "id": 5651,
                "therapyName": "BAY 1129980",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8854,
                    "pubMedId": 28292941,
                    "title": "Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28292941"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10824,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 1129980 inhibited tumor growth in a patient-derived xenograft (PDX) model of lung adenocarcinoma expressing high levels of LYPD3 (C4.4A) (PMID: 28292941).",
            "molecularProfile": {
                "id": 27809,
                "profileName": "LYPD3 positive"
            },
            "therapy": {
                "id": 5651,
                "therapyName": "BAY 1129980",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8854,
                    "pubMedId": 28292941,
                    "title": "Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28292941"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10820,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 1129980 decreased viability of LYPD3 (C4.4A)-expressing non-small cell lung cancer cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 28292941).",
            "molecularProfile": {
                "id": 27809,
                "profileName": "LYPD3 positive"
            },
            "therapy": {
                "id": 5651,
                "therapyName": "BAY 1129980",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8854,
                    "pubMedId": 28292941,
                    "title": "Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28292941"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10825,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 1129980 inhibited tumor growth in patient-derived xenograft (PDX) models of LYPD3 (C4.4A)-expressing lung squamous cell carcinoma (PMID: 28292941).",
            "molecularProfile": {
                "id": 27809,
                "profileName": "LYPD3 positive"
            },
            "therapy": {
                "id": 5651,
                "therapyName": "BAY 1129980",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8854,
                    "pubMedId": 28292941,
                    "title": "Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28292941"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27809,
            "profileName": "LYPD3 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}